This 2018 Clinical Therapeutics brief report by William J. Rea (Environmental Health Center–Dallas) describes treatment outcomes for 100 chemically sensitive, chronically mold-exposed patients evaluated from 2003–2013. Patients underwent mold identification, serum IgG anti-mold antibody assays, intradermal skin testing, urine trichothecene measurement, autonomic function testing, and neuropsychological assessment in subsets. Treatment combined mold avoidance, individualized intradermal antigen desensitization (mold mixes), and for some patients additional mycotoxin antigens, sauna, oxygen, and nutrient therapies. Overall outcomes: ~85% cleared completely, 14% partially improved, 1% unchanged. The paper reports high rates of positive intradermal reactivity (44%–98% for individual molds), autonomic abnormalities (~88%), neurocognitive deficits in 55% (mild–moderate), and immunologic T/B cell abnormalities. Limitations noted include heterogeneous exposures, lack of control group, and no post-treatment objective retesting.
Questions this document answers
100 patients; 61 female, 39 male; age range 21–78 years; mean age 44.3 years; studied 2003–2013.
Approximately 85% cleared completely; 14% had partial improvement; 1% remained unchanged.
Group A (25%): cleared with avoidance + intradermal antigen every 4 days for 3 months. Group B (25%): same as A plus additional antigens self-administered every 4 days for 3 months. Group C (25%): had urine mycotoxins and continued additional antigen injections daily for 18 months. Group D: 20% required continuous treatment ≥18 months and 5% did not improve.